-LCB-_-LRB-
The_DT
effect_NN
of_IN
24,25-dihydroxyvitamin_NN
D3_NN
-LRB-_-LRB-
dioxyvit_NN
-RRB-_-RRB-
on_IN
Ca_NN
metabolism_NN
and_CC
immune_JJ
status_NN
during_IN
chronic_JJ
kidney_NN
failure_NN
-RCB-_-RRB-

Active_JJ
metabolite_NN
of_IN
vitamin_NN
D3_NN
,_,
24R_NN
,25_CD
-LRB-_-LRB-
OH_NN
-RRB-_-RRB-
2D3_NN
-LRB-_-LRB-
dioxyvit_NN
-RRB-_-RRB-
was_VBD
used_VBN
at_IN
a_DT
daily_JJ
dose_NN
of_IN
100_CD
micrograms_NNS
in_IN
treatment_NN
of_IN
children_NNS
affected_VBN
with_IN
tubulointerstitial_JJ
disease_NN
of_IN
kidney_NN
and_CC
with_IN
chronic_JJ
glomerulonephritis_NN
under_IN
conditions_NNS
of_IN
kidney_NN
insufficiency_NN
._.

The_DT
drug_NN
exhibited_VBD
distinct_JJ
normalizing_NN
effect_NN
on_IN
patterns_NNS
of_IN
calcium_NN
metabolism_NN
:_:
increase_NN
of_IN
total_NN
and_CC
ionized_NNP
Ca2_NNP
+_NNP
and_CC
of_IN
25-OHD_NN
,_,
decrease_NN
in_IN
concentration_NN
of_IN
parath_NN
hormone_NN
and_CC
osteocalcine_NN
in_IN
blood_NN
serum_NN
as_RB
well_RB
as_IN
on_IN
immunological_JJ
parameters_NNS
:_:
restoration_NN
of_IN
decreased_JJ
content_NN
of_IN
T_NN
-_:
and_CC
0-lymphocytes_NNS
._.

Concentration_NN
of_IN
receptors_NNS
of_IN
hormonal_JJ
form_NN
of_IN
1,25_CD
-LRB-_-LRB-
OH_NN
-RRB-_-RRB-
2D3_NN
was_VBD
found_VBN
to_TO
be_VB
minimal_JJ
in_IN
lymphocytes_NNS
under_IN
conditions_NNS
of_IN
chronic_JJ
kidney_NN
insufficiency_NN
,_,
while_IN
their_PRP$
expression_NN
,_,
after_IN
the_DT
dioxyvit_NN
action_NN
,_,
was_VBD
detected_VBN
only_RB
in_IN
patients_NNS
with_IN
glomerulonephritis_NN
._.

Specific_JJ
calcitropic_NN
effect_NN
of_IN
dioxyvit_NN
with_IN
simultaneous_JJ
correction_NN
of_IN
vitamin_NN
D_NN
deficiency_NN
were_VBD
apparently_RB
responsible_JJ
for_IN
high_JJ
efficacy_NN
of_IN
the_DT
drug_NN
in_IN
treatment_NN
of_IN
calcium_NN
metabolism_NN
and_CC
immunity_NN
impairments_NNS
in_IN
children_NNS
with_IN
renal_JJ
deteriorations_NNS
at_IN
the_DT
step_NN
of_IN
chronic_JJ
kidney_NN
insufficiency_NN
._.

